Contribution of AcrAB efflux pump to ciprofloxacin resistance in Klebsiella pneumoniae isolated from burn patients

dgkh000215 10.3205/dgkh000215 urn:nbn:de:0183-dgkh0002154 Research Article Contribution of AcrAB efflux pump to ciprofloxacin resistance in Klebsiella pneumoniae isolated from burn patients Beitrag der AcrAB-Effluxpumpe zur Ciprofloxacin-Resistenz von Klebsiella pneumoniae, isoliert von Patienten mit Verbrennungen Pakzad Pakzad Iraj I

Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran

author Zayyen Karin Zayyen Karin Maasoume M

Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran

author Taherikalani Taherikalani Morovat M

Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

author Boustanshenas Boustanshenas Mina M

Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran

author Lari Lari Abdolaziz Rastegar AR PhD

Antimicrobial Resistance Research Center, Iran University of Medical Sciences, P.O. Box 14515-717, Tehran, Iran, Phone/Fax: +982182943183Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, IranDepartment of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

Lari@tums.ac.ir author German Medical Science GMS Publishing House

Düsseldorf

610 ciprofloxacin resistance efflux system Klebsiella pneumoniae Ciprofloxacinresistenz Effluxsystem Klebsiella pneumoniae 20131106 engl 2196-5226 8 2 GMS Hygiene and Infection Control GMS Hyg Infect Control 15 Ilam University of Medical Sciences Die Resistenz gegen Fluorchinolone ist in letzter Zeit bei von ambulanten Patienten isolierten Bakterienstämmen angestiegen. Multiresistente K. pneumoniae gehören zu den wichtigsten von Patienten mit Verbrennungen isolierten Mikroorganismen und die AcrAB-Effluxpumpe ist die hauptsächliche Effluxpumpe, die für die intrinsische Resistenz von K. pneumoniae gegen mehrere antimikrobielle Wirkstoffe einschließlich Ciprofloxacin und andere Fluorchinolone verantwortlich ist. Im Shahid Motahari Krankenhaus wurden 52 K. pneumoniae-Isolate von Patienten mit Verbrennungen durch konventionelle biochemische Tests bestätigt. Die antimikrobielle Empfindlichkeit der Isolate wurde gemäß der CLSI Guideline (2011) getestet. Bei Isolaten mit Ciprofloxacinresistenz wurde das acrA-Gen mit einem PCR-Assay bestimmt. Die MHK gegen Ciprofloxacin wurden mit und ohne den Entkoppler Carbonylcyanid-3-chlorphenylhydrazon (CCCP) bestimmt. Gemäß dem Breakpoint der CLSI Guideline waren alle 52 K. pneumoniae-Isolate der Verbrennungspatienten des Shahid Motahari Hospitals resistent gegen Ciprofloxacin. Der PCR-Assay für das acrA-Gen zeigte, dass alle Ciprofloxacin-resistenten Isolate das acrA-Gen enthielten, das das Membranfusionsprotein AcrA codiert und ein Teil des AcrAB-Effluxsystems ist. Nach Zugabe von CCCP als Inhibitor der Effluxpumpe zeigten 19 Stämme (47,5%) eine 2–32-fache Reduktion der MHK. Die anderen 21 Stämme (52,5%) zeigten keine Unterschiede in der MHK vor und nach Zugabe von CCCP. Zusammenfassend ist das AcrAB-Effluxsystem einer der wichtigsten Mechanismen für die Ciprofloxacinresistenz gegen K. pneumoniae, aber es gibt weitere Mechanismen wie die Mutation der Targetproteine der DNA-Gyrase des Topoisomerase-IV-Enzyms. Resistance to fluoroquinolones has been recently increased among bacterial strains isolated from outpatients. Multidrug-resistant K. pneumoniae is one of the major organisms isolated from burn patients and the AcrAB efflux pump is the principal pump contributing to the intrinsic resistance in K. pneumoniae against multiple antimicrobial agents including ciprofloxacin and other fluoroquinolones. Fifty-two K. pneumoniae isolated from burn patients in Shahid Motahari hospital and confirmed by conventional biochemical tests. Antimicrobial susceptibility testing was done according to CLSI 2011 guidelines, to determine the antimicrobial resistance pattern of isolates. AcrA gene was detected among ciprofloxacin-resistant isolates by PCR assay. MICs to ciprofloxacin were measured with and without carbonyl cyanide 3-chlorophenylhydrazone (CCCP)</PlainText></TextGroup>. Forty out of the 52 <TextGroup><Mark2>K. pneumoniae</Mark2></TextGroup> isolated from burn patients in Shahid Motahari hospital were resistant to ciprofloxacin according to breakpoint of CLSI guideline. PCR assay for <Mark2>acr</Mark2>A gene demonstrated that all ciprofloxacin-resistant isolates harbored <Mark2>acr</Mark2>A gene coding the membrane fusion protein AcrA and is a part of AcrAB efflux system. Among these isolates, 19 strains (47.5%) showed 2 to 32 fold reduction in MICs after using CCCP as an efflux pump inhibitor. The other 21 strains (52.5%) showed no disparity in MICs before and after using CCCP. In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among <Mark2>K. pneumoniae</Mark2> isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.</Pgraph></Abstract> <TextBlock linked="yes" name="1 Background"> <MainHeadline>1 Background</MainHeadline><Pgraph><Mark2>Klebsiella pneumoniae</Mark2> is one of the major agents in nosocomial infections that include infection of the urinary tract, the respiratory system, wounds and also the blood stream <TextLink reference="1"></TextLink>, <TextLink reference="2"></TextLink>. According to the data by the World Health Organization (WHO) a high amount of people die of pneumonia annually all over the world (<Hyperlink href="http://www.who.int/whr/2004/annex/en/index.html">http://www.who.int/whr/2004/annex/en/index.html</Hyperlink>). Appearance of multidrug-resistant species of <Mark2>K. pneumoniae</Mark2> has increased recently in the world <TextLink reference="3"></TextLink>. <Mark2>Klebsiella</Mark2> spp. have been found to harbor plasmids which is responsible for resistance to β-lactams especially extended-spectrum cephalosporins and also carbapenams <TextLink reference="4"></TextLink>. All these properties lead to difficult treatment of patients infected with multidrug resistant strains (MDR) of <Mark2>K. pneumoniae</Mark2> by using antimicrobial agents and the treatment will implicate a shift in strategies of fluoroquinolone usage. Resistance to fluoroquinolones has recently increased among bacterial strains isolated from outpatients <TextLink reference="5"></TextLink>. Fluoroquinolones resistantance mainly occurred through specific mutations in DNA gyrase and topoisomerase IV and over-expression of AcrAB multidrug efflux system. Both resistance mechanisms have been demonstrated in different organisms such as <Mark2>Escherichia coli</Mark2> <TextLink reference="6"></TextLink>, <Mark2>Pseudomonas aeruginosa</Mark2> <TextLink reference="7"></TextLink>, <Mark2>Staphylococcus aureus</Mark2> <TextLink reference="8"></TextLink>, <Mark2>Streptococcus pneumoniae</Mark2> <TextLink reference="9"></TextLink> and <Mark2>Klebsiella pneumoniae</Mark2> <TextLink reference="3"></TextLink>. Efflux pumps are transport proteins which are responsible for intrinsic or acquired resistance to different antibiotics based on chromosomal or plasmids sources of efflux genes, respectively. These proteins are found in both Gram-negative and -positive bacteria and extrude toxic substrates including antibiotics within cells into the external environment <TextLink reference="10"></TextLink>. AcrAB efflux pumps can change the permeability of the bacterial membrane by antibiotics extrusion to external environment thus the intracellular concentration of antibiotic reduces and the resistance to antibiotic will occur <TextLink reference="11"></TextLink>. Five major families of efflux pumps have been found in prokaryotic kingdom which AcrAB-TolC efflux pump has been classified as RND (resistance-nodulation-division) family. RND efflux pumps are one of the most important multidrug resistance efflux pumps and play a major role in multidrug resistance in bacteria by excreting antibiotics from different classes. CCCP is an uncoupler of oxidative phosphorylation, which disrupts the proton gradient of the membranes, required for activity of RND-type pumps including AcrAB thus AcrAB efflux pump have no inactivity in the present of CCCP <TextLink reference="11"></TextLink>. Over expression of genes belong to multidrug efflux pumps result in increasing resistance of bacteria against multiple drugs <TextLink reference="12"></TextLink>. AcrAB has been recognized as a principal pump contributing to the intrinsic resistance in <Mark2>E. coli</Mark2> against multiple antimicrobial agents <TextLink reference="13"></TextLink>, <TextLink reference="14"></TextLink>. Over expression of AcrAB was detected in other MDR strains of <Mark2>Enterobacteriaceae</Mark2> family such as <Mark2>Salmonella enterica</Mark2>, <Mark2>Enterobacter aerogenes</Mark2>, <Mark2>E. coli</Mark2>, <Mark2>Proteus mirabilis</Mark2>, and <Mark2>K. pneumoniae</Mark2> <TextLink reference="3"></TextLink>, <TextLink reference="13"></TextLink>, <TextLink reference="15"></TextLink>, <TextLink reference="16"></TextLink>, <TextLink reference="17"></TextLink>. AcrAB efflux pump can provide resistance against quinolones, chloramphenicol, tetracycline, trimethoprim, and β-lactams <TextLink reference="18"></TextLink>, <TextLink reference="19"></TextLink>, <TextLink reference="20"></TextLink>, <TextLink reference="21"></TextLink>, <TextLink reference="22"></TextLink>.</Pgraph><Pgraph>The aim of this study was to evaluate the presence of AcrAB efflux system by PCR assay and to demonstrate the role of active AcrAB efflux pump in resistance to ciprofloxacin among <Mark2>K. pneumoniae</Mark2> isolated from burn patients in Shahid Motahari hospital, Tehran (referral center of burn patients).</Pgraph></TextBlock> <TextBlock linked="yes" name="2 Materials and methods"> <MainHeadline>2 Materials and methods</MainHeadline><SubHeadline>2.1 Isolation of bacterial strains</SubHeadline><Pgraph>Fifty-two strains of <Mark2>Klebsiella pneumoniae</Mark2> were isolated during 6 months from hospitalized burn patients in Shahid Motahari Hospital, Tehran. Clinical conventional biochemical tests including triple sugar iron (TSI), urea, indole, ornithine decarboxylase, motility, growth in KCN medium, production of H<Subscript>2</Subscript>S , phenylalanine deaminase, simmons citrate test and etc. were performed for final identification of isolates. </Pgraph><SubHeadline>2.2 Antimicrobial susceptibility testing</SubHeadline><Pgraph>Antimicrobial susceptibility testing was performed by disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines 2011 <TextLink reference="23"></TextLink>. Each <Mark2>Klebsiella pneumoniae</Mark2> isolate was tested for susceptibility to 15 different antimicrobial agents including Imipenem (IMI), Ceftazidime (CAZ), Cefalosporine (CEF), Ticarcillin (TC), Aztreonam (AT), Tobramycin (TOB), Gentamicin (GN), Colistin (CO), Cefotaxime (CTX), Ciprofloxacin (CIP), Amikacin (AK), Cotrimoxazole (SXT), Piperacillin-tazobactam (PTZ), Piperacillin (PIP) and Tetracycline (TET) (MAST, Merseyside, U.K). <Mark2>E. coli</Mark2> ATCC 25922 was used as quality control for all antimicrobial susceptibility tests. According to CLSI guideline 2011, <Mark2>K. pneumoniae</Mark2> strain with zone of inhibition ≤15 mm for ciprofloxacin disk should be reported as ciprofloxacin-resistant strains. All the ciprofloxacin-resistant isolates subjected to evaluate MIC of ciprofloxacin by agar dilution technique according to CLSI guideline <TextLink reference="23"></TextLink>. </Pgraph><SubHeadline>2.3 Presence of AcrAB efflux pump among Ciprofiloxacin-resistant isolates </SubHeadline><Pgraph>Total genomic DNA was extracted by boiling method and used as a template for PCR reaction. Specific primers for <Mark2>Acr</Mark2>A gene (<Mark2>Acr</Mark2>A-F, 5´-ATGAACAAAAACAGAGG-3´ and <TextGroup><Mark2>Acr</Mark2><PlainText>A-R</PlainText></TextGroup>, 5´-TTTCAACGGCAGTTTTCG-3´) was used to evaluate the presence of AcrAB efflux pump. PCR reaction was performed in mixture, containing 1 × PCR buffer, 0.4mmol l<Superscript>–1</Superscript>dNTP, 0.7 mmol l<Superscript>–1</Superscript> Mgcl<Subscript>2</Subscript>, 10 pmol l<Superscript>–1</Superscript> of each primers, 1 U Taq DNA polymerase, 5 µl DNA template and distilled water up to final mixture volume of 25 µl and was done as follow: initial denaturation step at 94°C for 5 min followed by 30 cycles consisting of denaturation (94°C for 1 min), annealing (52°C for 1 min) and extension (72°C for 1 min), followed by a final extension step at 72°C for 5 min. PCR products were analyzed by electrophoresis in a 1% vw<Superscript>–1</Superscript>agarose gel. One of the PCR products was purified using QIAquick Gel Extraction Kit (Qiagen,Valencia, CA) and direct sequencing was done using ABI 3730X capillary sequencer (Macrogen, Seoul, Korea).</Pgraph><SubHeadline>2.4 Inhibition of efflux pump activity by CCCP</SubHeadline><Pgraph>The functionality of efflux pump was assessed by comparison the MICs to ciprofloxacin among resistant isolates before and after treatment with CCCP as an efflux pump inhibitor. CCCP can disrupt the proton gradient of the membrane and inhibit the activation of RND family efflux pumps including AcrAB pump <TextLink reference="11"></TextLink>. Addition of CCCP in Mueller-Hinton agar plates leads to an increase in intracellular concentration of antibiotics and consequently, reduce the MIC value in isolates carrying active efflux pumps. MIC to ciprofloxacin among 40 ciprofloxacin-resistant isolates was determined in Mueller-Hinton Agar plates containing different concentration of ciprofloxacin from 0.5 to 256 µg ml<Superscript>–1</Superscript> according to CLSI guideline, 2011 <TextLink reference="23"></TextLink>, <Mark2>E. coli</Mark2> ATCC 25922 was used as control. To compare the AcrAB efflux pump activity in presence inhibitor, CCCP was added to each Mueller-Hinton agar plates containing 0.5–256 µg ml<Superscript>–1</Superscript> of ciprofloxacin at final concentration of 25 µg ml<Superscript>–1</Superscript>. Plates containing CCCP but no ciprofloxacin were used as control.</Pgraph></TextBlock> <TextBlock linked="yes" name="3 Results"> <MainHeadline>3 Results</MainHeadline><SubHeadline>3.1 Bacterial isolates and antibiotic resistance pattern</SubHeadline><Pgraph>Forty isolates out of 52 (77%) were resistant to ciprofloxacin and all of the ciprofloxacin-resistant isolates were resistant to tetracycline. Thirty-eight (95%) of ciprofloxacin-resistant isolates were resistant to tetracycline, imipenem, ceftazidime, cefalosporine, ticarcillin, aztreonam, tobramycin and gentamicin since they showed resistance to three different groups of antibiotics were reported as multidrug resistant (MDR) strains. The two remain strains were resistant to mentioned antibiotics except imipenem.</Pgraph><SubHeadline>3.2 Molecular detection of acrA gene </SubHeadline><Pgraph>PCR assay using specific primers for <Mark2>acr</Mark2>A gene demonstrated that all ciprofloxacin-resistant strains harbored <Mark2>acr</Mark2>A gene and consequently contain AcrAB efflux system. PCR amplification products of <Mark2>acr</Mark2>A gene among clinical ciprofloxacin-resistant isolates was shown in Figure 1 <ImgLink imgNo="1" imgType="figure"/>, the expected 495 bp DNA fragment was belonged to <Mark2>acr</Mark2>A gene. Sequence analysis showed that these amplification products corresponded to <Mark2>acr</Mark2>A gene of <Mark2>Klebsiella pneumoniae</Mark2>.</Pgraph><SubHeadline>3.3 Inhibitory effect of CCCP on the AcrAB efflux system</SubHeadline><Pgraph>MIC value for ciprofloxacin resistance was determined in presence of 25 µg ml<Superscript>–1</Superscript> of CCCP as efflux pump inhibitor to evaluate the role of active AcrAB efflux system in resistance to ciprofloxacin among CIP-resistant isolates. Comparison of MIC value with and without CCCP showed a significant reduction from 2- to 32-fold after using <TextGroup><PlainText>25 µg ml</PlainText><Superscript>–1</Superscript></TextGroup> of CCCP among 19 out of 40 (47.5%) ciprofloxacin-resistant isolates. Among these former isolates 2 (10.6%) isolates showed 32-fold reduction in MIC, <TextGroup><PlainText>1 (5.2%)</PlainText></TextGroup> isolate showed 16-fold reduction, 6 (31.6%) isolates8-fold, 4 (21%) isolates and 6 (31.6%) isolates showed 4-fold and 2-fold reduction in MIC, respectively. Twenty-one out of 40 (52.5%) ciprofloxacin-resistant isolates illustrated no differences in MIC value before and after using CCCP (Table 1 <ImgLink imgNo="1" imgType="table"/>).</Pgraph></TextBlock> <TextBlock linked="yes" name="4 Discussion"> <MainHeadline>4 Discussion</MainHeadline><Pgraph>Recent studies indicated that emergence of ciprofloxacin-resistant clinical isolates and multidrug resistant <TextGroup><Mark2>K. pneumoniae</Mark2></TextGroup> strains have been increased among burn patients in Iran <TextLink reference="24"></TextLink>, <TextLink reference="25"></TextLink>. Burn patients are at the high risk of gram negative bacilli including <TextGroup><Mark2>K. pneumoniae</Mark2></TextGroup> infections, especially in the pediatric burn cases when infected with multidrug resistant strains <TextLink reference="26"></TextLink>, <TextLink reference="27"></TextLink>. Present study demonstrated that 95% of ciprofloxacin-resistant isolates were multidrug resistant indicating the importance of MDR strains of <TextGroup><Mark2>K. pneumoniae</Mark2></TextGroup> among burn patients. Recent studies indicated many different mechanisms for antimicrobial resistance ability among bacteria; one of the most important mechanisms is efflux pumps including AcrAB efflux system. Many studies have been performed to investigate the relation between AcrAB efflux system and resistance to fluoroquinolones in <Mark2>K. pneumoniae</Mark2> <TextLink reference="3"></TextLink>, <TextLink reference="28"></TextLink> and other bacteria <TextLink reference="6"></TextLink>. Different inhibitors including phenylalanine arginine β-naphthylamide (PAβN) or carbonyl cyanide 3-chlorophenylhydrazone (CCCP) have been used to evaluate the effect of AcrAB efflux pump in ciprofloxacin resistance property among <Mark2>K. pneumoniae</Mark2> strains <TextLink reference="28"></TextLink>, <TextLink reference="29"></TextLink>. </Pgraph><Pgraph>In the present study, MICs of ciprofloxacin were measured with and without CCCP as an AcrAB efflux pump inhibitor. The results revealed that 47.5% of ciprofloxacin-resistant isolates showed reduction from 2- to 32-fold in MICs of ciprofloxacin after using CCCP which is represented the high resistance to ciprofloxacin (over 256 µg ml<Superscript>–1</Superscript>) among isolates. The results of this study in reduction of MICs after using CCCP are consistent with other studies <TextLink reference="29"></TextLink>.</Pgraph><Pgraph>In another study performed by Hasdemir and colleagues (2004), it has been revealed that AcrAB efflux pump contribute to resistance to quinolones, chloramphenicol, tetracycline, and β-lactams in multidrug resistant <TextGroup><Mark2>K. pneumonia</Mark2></TextGroup> isolated from Turkey <TextLink reference="28"></TextLink>. In the present study, simultaneous resistance to ciprofloxacin, tetracycline and <TextGroup><PlainText>β-lactams</PlainText></TextGroup> was observed among isolate with reduction in MICs to ciprofloxacin after using CCCP. Although, the PCR assay showed that all the ciprofloxacin-resistant isolates harbored the <Mark2>acr</Mark2>A gene but 47.5% of isolated showed reduction in MICs to ciprofloxacin after using CCCP, which is confirmed the contribution of AcrAB efflux pump in ciprofloxacin resistance in these isolates. In the study by Hasdemir and colleagues (2004), reduction in MICs to ciprofloxacin after using pump inhibitor has been reported among 39% of isolates. In the present study, the remaining 52.5% of isolates showed no changing in MICs after using CCCP thus other mechanisms as mutation in target proteins of DNA gyrase and topoisomerase IV enzymes or harboring the <Mark2>qnr</Mark2> genes which are responsible for resistance to fluoroquinolones probably involved in ciprofloxacin resistance of the strains <TextLink reference="22"></TextLink>, <TextLink reference="30"></TextLink>.</Pgraph></TextBlock> <TextBlock linked="yes" name="5 Conclusions"> <MainHeadline>5 Conclusions</MainHeadline><Pgraph>In conclusion the AcrAB efflux system is one of the major mechanisms in multidrug resistant <Mark2>K. pneumoniae</Mark2> strains. Ciprofloxacin acts as substrate for AcrAB efflux pump and consequently reduces the intracellular concentration of antibiotics. In this study, the relation between AcrAB efflux pump and resistance to ciprofloxacin was confirmed.</Pgraph></TextBlock> <TextBlock linked="yes" name="Notes"> <MainHeadline>Notes</MainHeadline><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph><SubHeadline>Funding</SubHeadline><Pgraph>This study was supported by Ilam University of Medical Sciences, grant no. 921008/48.</Pgraph></TextBlock> <References linked="yes"> <Reference refNo="1"> <RefAuthor>Struve C</RefAuthor> <RefAuthor>Krogfelt KA</RefAuthor> <RefTitle>Pathogenic potential of environmental Klebsiella pneumoniae isolates</RefTitle> <RefYear>2004</RefYear> <RefJournal>Environ Microbiol</RefJournal> <RefPage>584-90</RefPage> <RefTotal>Struve C, Krogfelt KA. Pathogenic potential of environmental Klebsiella pneumoniae isolates. Environ Microbiol. 2004 Jun;6(6):584-90. DOI: 10.1111/j.1462-2920.2004.00590.x </RefTotal> <RefLink>http://dx.doi.org/10.1111/j.1462-2920.2004.00590.x</RefLink> </Reference> <Reference refNo="2"> <RefAuthor>Varon NF</RefAuthor> <RefAuthor>Alangaden GJ</RefAuthor> <RefTitle>Emerging trends in infections among renal transplant recipients</RefTitle> <RefYear>2004</RefYear> <RefJournal>Expert Rev Anti Infect Ther</RefJournal> <RefPage>95-109</RefPage> <RefTotal>Varon NF, Alangaden GJ. Emerging trends in infections among renal transplant recipients. Expert Rev Anti Infect Ther. 2004 Feb;2(1):95-109. DOI: 10.1586/14787210.2.1.95 </RefTotal> <RefLink>http://dx.doi.org/10.1586/14787210.2.1.95</RefLink> </Reference> <Reference refNo="3"> <RefAuthor>Mazzariol A</RefAuthor> <RefAuthor>Zuliani J</RefAuthor> <RefAuthor>Cornaglia G</RefAuthor> <RefAuthor>Rossolini GM</RefAuthor> <RefAuthor>Fontana R</RefAuthor> <RefTitle>AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp</RefTitle> <RefYear>2002</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>3984-6</RefPage> <RefTotal>Mazzariol A, Zuliani J, Cornaglia G, Rossolini GM, Fontana R. AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp. Antimicrob Agents Chemother. 2002 Dec;46(12):3984-6. DOI: 10.1128/AAC.46.12.3984-3986.2002 </RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.46.12.3984-3986.2002</RefLink> </Reference> <Reference refNo="4"> <RefAuthor>Poirel L</RefAuthor> <RefAuthor>Héritier C</RefAuthor> <RefAuthor>Podglajen I</RefAuthor> <RefAuthor>Sougakoff W</RefAuthor> <RefAuthor>Gutmann L</RefAuthor> <RefAuthor>Nordmann P</RefAuthor> <RefTitle>Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem</RefTitle> <RefYear>2003</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>755-8</RefPage> <RefTotal>Poirel L, Héritier C, Podglajen I, Sougakoff W, Gutmann L, Nordmann P. Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem. Antimicrob Agents Chemother. 2003 Feb;47(2):755-8. DOI: 10.1128/AAC.47.2.755-758.2003 </RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.47.2.755-758.2003</RefLink> </Reference> <Reference refNo="5"> <RefAuthor>Garau J</RefAuthor> <RefAuthor>Xercavins M</RefAuthor> <RefAuthor>Rodríguez-Carballeira M</RefAuthor> <RefAuthor>Gómez-Vera JR</RefAuthor> <RefAuthor>Coll I</RefAuthor> <RefAuthor>Vidal D</RefAuthor> <RefAuthor>Llovet T</RefAuthor> <RefAuthor>Ruíz-Bremón A</RefAuthor> <RefTitle>Emergence and dissemination of quinolone-resistant Escherichia coli in the community</RefTitle> <RefYear>1999</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>2736-41</RefPage> <RefTotal>Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, Llovet T, Ruíz-Bremón A. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999 Nov;43(11):2736-41.</RefTotal> </Reference> <Reference refNo="6"> <RefAuthor>Mazzariol A</RefAuthor> <RefAuthor>Tokue Y</RefAuthor> <RefAuthor>Kanegawa TM</RefAuthor> <RefAuthor>Cornaglia G</RefAuthor> <RefAuthor>Nikaido H</RefAuthor> <RefTitle>High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA</RefTitle> <RefYear>2000</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>3441-3</RefPage> <RefTotal>Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H. High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother. 2000 Dec;44(12):3441-3. DOI: 10.1128/AAC.44.12.3441-3443.2000 </RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.44.12.3441-3443.2000</RefLink> </Reference> <Reference refNo="7"> <RefAuthor>Le Thomas I</RefAuthor> <RefAuthor>Couetdic G</RefAuthor> <RefAuthor>Clermont O</RefAuthor> <RefAuthor>Brahimi N</RefAuthor> <RefAuthor>Plésiat P</RefAuthor> <RefAuthor>Bingen E</RefAuthor> <RefTitle>In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy</RefTitle> <RefYear>2001</RefYear> <RefJournal>J Antimicrob Chemother</RefJournal> <RefPage>553-5</RefPage> <RefTotal>Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plésiat P, Bingen E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother. 2001 Oct;48(4):553-5. DOI: 10.1093/jac/48.4.553 </RefTotal> <RefLink>http://dx.doi.org/10.1093/jac/48.4.553</RefLink> </Reference> <Reference refNo="8"> <RefAuthor>Kaatz GW</RefAuthor> <RefAuthor>Seo SM</RefAuthor> <RefAuthor>Ruble CA</RefAuthor> <RefTitle>Mechanisms of fluoroquinolone resistance in Staphylococcus aureus</RefTitle> <RefYear>1991</RefYear> <RefJournal>J Infect Dis</RefJournal> <RefPage>1080-6</RefPage> <RefTotal>Kaatz GW, Seo SM, Ruble CA. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis. 1991 May;163(5):1080-6. DOI: 10.1093/infdis/163.5.1080 </RefTotal> <RefLink>http://dx.doi.org/10.1093/infdis/163.5.1080</RefLink> </Reference> <Reference refNo="9"> <RefAuthor>Jones ME</RefAuthor> <RefAuthor>Sahm DF</RefAuthor> <RefAuthor>Martin N</RefAuthor> <RefAuthor>Scheuring S</RefAuthor> <RefAuthor>Heisig P</RefAuthor> <RefAuthor>Thornsberry C</RefAuthor> <RefAuthor>Köhrer K</RefAuthor> <RefAuthor>Schmitz FJ</RefAuthor> <RefTitle>Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season</RefTitle> <RefYear>2000</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>462-6</RefPage> <RefTotal>Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, Köhrer K, Schmitz FJ. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother. 2000 Feb;44(2):462-6. DOI: 10.1128/AAC.44.2.462-466.2000 </RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.44.2.462-466.2000</RefLink> </Reference> <Reference refNo="10"> <RefAuthor>Van Bambeke F</RefAuthor> <RefAuthor>Balzi E</RefAuthor> <RefAuthor>Tulkens PM</RefAuthor> <RefTitle>Antibiotic efflux pumps</RefTitle> <RefYear>2000</RefYear> <RefJournal>Biochem Pharmacol</RefJournal> <RefPage>457-70</RefPage> <RefTotal>Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol. 2000 Aug 15;60(4):457-70. DOI: 10.1016/S0006-2952(00)00291-4</RefTotal> <RefLink>http://dx.doi.org/10.1016/S0006-2952(00)00291-4</RefLink> </Reference> <Reference refNo="11"> <RefAuthor>Peleg AY</RefAuthor> <RefAuthor>Adams J</RefAuthor> <RefAuthor>Paterson DL</RefAuthor> <RefTitle>Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii</RefTitle> <RefYear>2007</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>2065-9</RefPage> <RefTotal>Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007 Jun;51(6):2065-9. DOI: 10.1128/AAC.01198-06</RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.01198-06</RefLink> </Reference> <Reference refNo="12"> <RefAuthor>Nikaido H</RefAuthor> <RefTitle>Antibiotic resistance caused by gram-negative multidrug efflux pumps</RefTitle> <RefYear>1998</RefYear> <RefJournal>Clin Infect Dis</RefJournal> <RefPage>S32-41</RefPage> <RefTotal>Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis. 1998 Aug;27 Suppl 1:S32-41. DOI: 10.1086/514920</RefTotal> <RefLink>http://dx.doi.org/10.1086/514920</RefLink> </Reference> <Reference refNo="13"> <RefAuthor>Okusu H</RefAuthor> <RefAuthor>Ma D</RefAuthor> <RefAuthor>Nikaido H</RefAuthor> <RefTitle>AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants</RefTitle> <RefYear>1996</RefYear> <RefJournal>J Bacteriol</RefJournal> <RefPage>306-8</RefPage> <RefTotal>Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol. 1996;178(1):306-8.</RefTotal> </Reference> <Reference refNo="14"> <RefAuthor>Fralick JA</RefAuthor> <RefTitle>Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli</RefTitle> <RefYear>1996</RefYear> <RefJournal>J Bacteriol</RefJournal> <RefPage>5803-5</RefPage> <RefTotal>Fralick JA. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol. 1996 Oct;178(19):5803-5. </RefTotal> </Reference> <Reference refNo="15"> <RefAuthor>Piddock LJ</RefAuthor> <RefAuthor>White DG</RefAuthor> <RefAuthor>Gensberg K</RefAuthor> <RefAuthor>Pumbwe L</RefAuthor> <RefAuthor>Griggs DJ</RefAuthor> <RefTitle>Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium</RefTitle> <RefYear>2000</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>3118-21</RefPage> <RefTotal>Piddock LJ, White DG, Gensberg K, Pumbwe L, Griggs DJ. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother. 2000 Nov;44(11):3118-21. DOI: 10.1128/AAC.44.11.3118-3121.2000 </RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.44.11.3118-3121.2000</RefLink> </Reference> <Reference refNo="16"> <RefAuthor>Pradel E</RefAuthor> <RefAuthor>Pagès JM</RefAuthor> <RefTitle>The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes</RefTitle> <RefYear>2002</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>2640-3</RefPage> <RefTotal>Pradel E, Pagès JM. The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob Agents Chemother. 2002 Aug;46(8):2640-3. DOI: 10.1128/AAC.46.8.2640-2643.2002 </RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.46.8.2640-2643.2002</RefLink> </Reference> <Reference refNo="17"> <RefAuthor>Visalli MA</RefAuthor> <RefAuthor>Murphy E</RefAuthor> <RefAuthor>Projan SJ</RefAuthor> <RefAuthor>Bradford PA</RefAuthor> <RefTitle>AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis</RefTitle> <RefYear>2003</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>665-9</RefPage> <RefTotal>Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother. 2003 Feb;47(2):665-9. DOI: 10.1128/AAC.47.2.665-669.2003 </RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.47.2.665-669.2003</RefLink> </Reference> <Reference refNo="18"> <RefAuthor>Bialek S</RefAuthor> <RefAuthor>Lavigne JP</RefAuthor> <RefAuthor>Chevalier J</RefAuthor> <RefAuthor>Marcon E</RefAuthor> <RefAuthor>Leflon-Guibout V</RefAuthor> <RefAuthor>Davin A</RefAuthor> <RefAuthor>Moreau R</RefAuthor> <RefAuthor>Pagès JM</RefAuthor> <RefAuthor>Nicolas-Chanoine MH</RefAuthor> <RefTitle>Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model</RefTitle> <RefYear>2010</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>4373-8</RefPage> <RefTotal>Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pagès JM, Nicolas-Chanoine MH. Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model. Antimicrob Agents Chemother. 2010 Oct;54(10):4373-8. DOI: 10.1128/AAC.01607-09</RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.01607-09</RefLink> </Reference> <Reference refNo="19"> <RefAuthor>Nikaido H</RefAuthor> <RefAuthor>Takatsuka Y</RefAuthor> <RefTitle>Mechanisms of RND multidrug efflux pumps</RefTitle> <RefYear>2009</RefYear> <RefJournal>Biochim Biophys Acta</RefJournal> <RefPage>769-81</RefPage> <RefTotal>Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta. 2009 May;1794(5):769-81. DOI: 10.1016/j.bbapap.2008.10.004</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.bbapap.2008.10.004</RefLink> </Reference> <Reference refNo="20"> <RefAuthor>Piddock LJ</RefAuthor> <RefTitle>Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria</RefTitle> <RefYear>2006</RefYear> <RefJournal>Clin Microbiol Rev</RefJournal> <RefPage>382-402</RefPage> <RefTotal>Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006 Apr;19(2):382-402. DOI: 10.1128/CMR.19.2.382-402.2006</RefTotal> <RefLink>http://dx.doi.org/10.1128/CMR.19.2.382-402.2006</RefLink> </Reference> <Reference refNo="21"> <RefAuthor>Ruzin A</RefAuthor> <RefAuthor>Visalli MA</RefAuthor> <RefAuthor>Keeney D</RefAuthor> <RefAuthor>Bradford PA</RefAuthor> <RefTitle>Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae</RefTitle> <RefYear>2005</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>1017-22</RefPage> <RefTotal>Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2005 Mar;49(3):1017-22. DOI: 10.1128/AAC.49.3.1017-1022.2005</RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.49.3.1017-1022.2005</RefLink> </Reference> <Reference refNo="22"> <RefAuthor>Schneiders T</RefAuthor> <RefAuthor>Amyes SG</RefAuthor> <RefAuthor>Levy SB</RefAuthor> <RefTitle>Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore</RefTitle> <RefYear>2003</RefYear> <RefJournal>Antimicrob Agents Chemother</RefJournal> <RefPage>2831-7</RefPage> <RefTotal>Schneiders T, Amyes SG, Levy SB. Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob Agents Chemother. 2003 Sep;47(9):2831-7. DOI: 10.1128/AAC.47.9.2831-2837.2003</RefTotal> <RefLink>http://dx.doi.org/10.1128/AAC.47.9.2831-2837.2003</RefLink> </Reference> <Reference refNo="23"> <RefAuthor>Clinical and Laboratory Standards Institute</RefAuthor> <RefTitle></RefTitle> <RefYear>2010</RefYear> <RefBookTitle>Performance standards for antimicrobial susceptibility testing: 20th informational supplement</RefBookTitle> <RefPage></RefPage> <RefTotal>Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. Wayne, PA: CLSI; 2010. (CLSI document; M100-S20).</RefTotal> </Reference> <Reference refNo="24"> <RefAuthor>Alaghehbandan R</RefAuthor> <RefAuthor>Azimi L</RefAuthor> <RefAuthor>Rastegar Lari A</RefAuthor> <RefTitle>Nosocomial infections among burn patients in Teheran, Iran: a decade later</RefTitle> <RefYear>2012</RefYear> <RefJournal>Ann Burns Fire Disasters</RefJournal> <RefPage>3-7</RefPage> <RefTotal>Alaghehbandan R, Azimi L, Rastegar Lari A. Nosocomial infections among burn patients in Teheran, Iran: a decade later. Ann Burns Fire Disasters. 2012 Mar;25(1):3-7. </RefTotal> </Reference> <Reference refNo="25"> <RefAuthor>Rastegar Lari A</RefAuthor> <RefAuthor>Azimi L</RefAuthor> <RefAuthor>Rahbar M</RefAuthor> <RefAuthor>Fallah F</RefAuthor> <RefAuthor>Alaghehbandan R</RefAuthor> <RefTitle>Phenotypic detection of Klebsiella pneumoniae carbapenemase among burns patients: first report from Iran</RefTitle> <RefYear>2013</RefYear> <RefJournal>Burns</RefJournal> <RefPage>174-6</RefPage> <RefTotal>Rastegar Lari A, Azimi L, Rahbar M, Fallah F, Alaghehbandan R. Phenotypic detection of Klebsiella pneumoniae carbapenemase among burns patients: first report from Iran. Burns. 2013 Feb;39(1):174-6. DOI: 10.1016/j.burns.2012.02.025</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.burns.2012.02.025</RefLink> </Reference> <Reference refNo="26"> <RefAuthor>Azimi L</RefAuthor> <RefAuthor>Rastegar Lari A</RefAuthor> <RefAuthor>Alaghehbandan R</RefAuthor> <RefAuthor>Alinejad F</RefAuthor> <RefAuthor>Mohammadpoor M</RefAuthor> <RefAuthor>Rahbar M</RefAuthor> <RefTitle>KPC-producer gram negative bacteria among burned infants in Motahari Hospital, Tehran: first report from Iran</RefTitle> <RefYear>2012</RefYear> <RefJournal>Ann Burns Fire Disasters</RefJournal> <RefPage>74-7</RefPage> <RefTotal>Azimi L, Rastegar Lari A, Alaghehbandan R, Alinejad F, Mohammadpoor M, Rahbar M. KPC-producer gram negative bacteria among burned infants in Motahari Hospital, Tehran: first report from Iran. Ann Burns Fire Disasters. 2012 Jun;25(2):74-7.</RefTotal> </Reference> <Reference refNo="27"> <RefAuthor>Zorgani A</RefAuthor> <RefAuthor>Franka RA</RefAuthor> <RefAuthor>Zaidi MM</RefAuthor> <RefAuthor>Alshweref UM</RefAuthor> <RefAuthor>Elgmati M</RefAuthor> <RefTitle>Trends in nosocomial bloodstream infections in a burn intensive care unit: an eight-year survey</RefTitle> <RefYear>2010</RefYear> <RefJournal>Ann Burns Fire Disasters</RefJournal> <RefPage>88-94</RefPage> <RefTotal>Zorgani A, Franka RA, Zaidi MM, Alshweref UM, Elgmati M. Trends in nosocomial bloodstream infections in a burn intensive care unit: an eight-year survey. Ann Burns Fire Disasters. 2010 Jun;23(2):88-94.</RefTotal> </Reference> <Reference refNo="28"> <RefAuthor>Hasdemir UO</RefAuthor> <RefAuthor>Chevalier J</RefAuthor> <RefAuthor>Nordmann P</RefAuthor> <RefAuthor>Pagès JM</RefAuthor> <RefTitle>Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey</RefTitle> <RefYear>2004</RefYear> <RefJournal>J Clin Microbiol</RefJournal> <RefPage>2701-6</RefPage> <RefTotal>Hasdemir UO, Chevalier J, Nordmann P, Pagès JM. Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol. 2004 Jun;42(6):2701-6. DOI: 10.1128/JCM.42.6.2701-2706.2004</RefTotal> <RefLink>http://dx.doi.org/10.1128/JCM.42.6.2701-2706.2004</RefLink> </Reference> <Reference refNo="29"> <RefAuthor>Aathithan S</RefAuthor> <RefAuthor>French GL</RefAuthor> <RefTitle>Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of Klebsiella pneumoniae</RefTitle> <RefYear>2011</RefYear> <RefJournal>Eur J Clin Microbiol Infect Dis</RefJournal> <RefPage>745-52</RefPage> <RefTotal>Aathithan S, French GL. Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2011 Jun;30(6):745-52. DOI: 10.1007/s10096-010-1147-0</RefTotal> <RefLink>http://dx.doi.org/10.1007/s10096-010-1147-0</RefLink> </Reference> <Reference refNo="30"> <RefAuthor>Cattoir V</RefAuthor> <RefAuthor>Poirel L</RefAuthor> <RefAuthor>Rotimi V</RefAuthor> <RefAuthor>Soussy CJ</RefAuthor> <RefAuthor>Nordmann P</RefAuthor> <RefTitle>Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates</RefTitle> <RefYear>2007</RefYear> <RefJournal>J Antimicrob Chemother</RefJournal> <RefPage>394-7</RefPage> <RefTotal>Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother. 2007 Aug;60(2):394-7. DOI: 10.1093/jac/dkm204</RefTotal> <RefLink>http://dx.doi.org/10.1093/jac/dkm204</RefLink> </Reference> </References> <Media> <Tables> <Table format="png"> <MediaNo>1</MediaNo> <MediaID>1</MediaID> <Caption><Pgraph><Mark1>Table 1: MICs of ciprofloxacin with and without CCCP in </Mark1><Mark1><Mark2>K. pneumonia</Mark2></Mark1><Mark1> isolates</Mark1></Pgraph></Caption> </Table> <NoOfTables>1</NoOfTables> </Tables> <Figures> <Figure format="png" height="332" width="567"> <MediaNo>1</MediaNo> <MediaID>1</MediaID> <Caption><Pgraph><Mark1>Figure 1: PCR amplification of </Mark1><Mark1><Mark2>acrA </Mark2></Mark1><Mark1>gene in ciprofloxacin-resistant </Mark1><Mark1><Mark2>Klebsiella pneumonia</Mark2></Mark1> </Pgraph><Pgraph>Lane 1: 1500 bp DNA size marker; Lane2: Positive control for <Mark2>acrA</Mark2> gene; 3–6: PCR product of <Mark2>acr</Mark2>A gene (495 bp) in ciprofloxacin-resistant <Mark2>K. pneumonia</Mark2> strains; Lane 7: negative control.</Pgraph></Caption> </Figure> <NoOfPictures>1</NoOfPictures> </Figures> <InlineFigures> <NoOfPictures>0</NoOfPictures> </InlineFigures> <Attachments> <NoOfAttachments>0</NoOfAttachments> </Attachments> </Media> </OrigData> </GmsArticle>